IL90975A - Non-glycosylated, recombinant human il2 in reduced form, the process for obtaining it and its use as a medicament - Google Patents

Non-glycosylated, recombinant human il2 in reduced form, the process for obtaining it and its use as a medicament

Info

Publication number: IL90975A
Authority: IL; Israel
Prior art keywords: leu; thr; glu; lys; asn
Prior art date: 1988-07-28

Application number

IL9097589A

Other languages

English (en)

Other versions

IL90975A0 (en

Original Assignee

Roussel Uclaf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-07-28

Filing date

1989-07-14

Publication date

1994-11-28

1989-07-14 Application filed by Roussel Uclaf filed Critical Roussel Uclaf

1990-02-09 Publication of IL90975A0 publication Critical patent/IL90975A0/xx

1994-11-28 Publication of IL90975A publication Critical patent/IL90975A/en

Links

238000000034 method Methods 0.000 title claims abstract description 32
230000008569 process Effects 0.000 title claims abstract description 24
239000003814 drug Substances 0.000 title claims abstract description 8
102000000588 Interleukin-2 Human genes 0.000 claims abstract description 54
108010002350 Interleukin-2 Proteins 0.000 claims abstract description 54
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract description 14
230000004071 biological effect Effects 0.000 claims abstract description 14
102000055277 human IL2 Human genes 0.000 claims abstract description 14
235000018417 cysteine Nutrition 0.000 claims abstract description 9
150000001945 cysteines Chemical class 0.000 claims abstract 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 42
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 38
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
239000007864 aqueous solution Substances 0.000 claims description 13
238000001816 cooling Methods 0.000 claims description 13
239000000243 solution Substances 0.000 claims description 13
239000008346 aqueous phase Substances 0.000 claims description 10
229930182817 methionine Natural products 0.000 claims description 10
150000007524 organic acids Chemical class 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
239000012071 phase Substances 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 9
235000001014 amino acid Nutrition 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 9
238000010790 dilution Methods 0.000 claims description 8
239000012895 dilution Substances 0.000 claims description 8
239000008187 granular material Substances 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 7
108010025306 histidylleucine Proteins 0.000 claims description 7
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 7
238000000746 purification Methods 0.000 claims description 7
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 claims description 6
244000005700 microbiome Species 0.000 claims description 6
238000000926 separation method Methods 0.000 claims description 6
238000004128 high performance liquid chromatography Methods 0.000 claims description 5
WDIYWDJLXOCGRW-ACZMJKKPSA-N Ala-Asp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WDIYWDJLXOCGRW-ACZMJKKPSA-N 0.000 claims description 4
OISWSORSLQOGFV-AVGNSLFASA-N Arg-Met-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCCN=C(N)N OISWSORSLQOGFV-AVGNSLFASA-N 0.000 claims description 4
WKPXXXUSUHAXDE-SRVKXCTJSA-N Arg-Pro-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WKPXXXUSUHAXDE-SRVKXCTJSA-N 0.000 claims description 4
BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 claims description 4
KWBQPGIYEZKDEG-FSPLSTOPSA-N Asn-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O KWBQPGIYEZKDEG-FSPLSTOPSA-N 0.000 claims description 4
AOZBJZBKFHOYHL-AVGNSLFASA-N Cys-Glu-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O AOZBJZBKFHOYHL-AVGNSLFASA-N 0.000 claims description 4
XLLSMEFANRROJE-GUBZILKMSA-N Cys-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N XLLSMEFANRROJE-GUBZILKMSA-N 0.000 claims description 4
MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 claims description 4
QJCKNLPMTPXXEM-AUTRQRHGSA-N Glu-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O QJCKNLPMTPXXEM-AUTRQRHGSA-N 0.000 claims description 4
IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 claims description 4
IGUOAYLTQJLPPD-DCAQKATOSA-N Leu-Asn-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IGUOAYLTQJLPPD-DCAQKATOSA-N 0.000 claims description 4
OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 claims description 4
JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 claims description 4
IWTBYNQNAPECCS-AVGNSLFASA-N Leu-Glu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IWTBYNQNAPECCS-AVGNSLFASA-N 0.000 claims description 4
PDQDCFBVYXEFSD-SRVKXCTJSA-N Leu-Leu-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PDQDCFBVYXEFSD-SRVKXCTJSA-N 0.000 claims description 4
LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 claims description 4
NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 claims description 4
OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 claims description 4
HYSVGEAWTGPMOA-IHRRRGAJSA-N Lys-Pro-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O HYSVGEAWTGPMOA-IHRRRGAJSA-N 0.000 claims description 4
VADLTGVIOIOKGM-BZSNNMDCSA-N Phe-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CN=CN1 VADLTGVIOIOKGM-BZSNNMDCSA-N 0.000 claims description 4
ZTVSVSFBHUVYIN-UFYCRDLUSA-N Phe-Tyr-Met Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=C(O)C=C1 ZTVSVSFBHUVYIN-UFYCRDLUSA-N 0.000 claims description 4
DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 claims description 4
LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 claims description 4
GZBKRJVCRMZAST-XKBZYTNZSA-N Ser-Glu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZBKRJVCRMZAST-XKBZYTNZSA-N 0.000 claims description 4
HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 claims description 4
XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 claims description 4
NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 claims description 4
CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 claims description 4
MGJLBZFUXUGMML-VOAKCMCISA-N Thr-Lys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MGJLBZFUXUGMML-VOAKCMCISA-N 0.000 claims description 4
UGFSAPWZBROURT-IXOXFDKPSA-N Thr-Phe-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N)O UGFSAPWZBROURT-IXOXFDKPSA-N 0.000 claims description 4
VGYVVSQFSSKZRJ-OEAJRASXSA-N Thr-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1 VGYVVSQFSSKZRJ-OEAJRASXSA-N 0.000 claims description 4
BDYBHQWMHYDRKJ-UNQGMJICSA-N Thr-Phe-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O)N)O BDYBHQWMHYDRKJ-UNQGMJICSA-N 0.000 claims description 4
FOADDSDHGRFUOC-DZKIICNBSA-N Val-Glu-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FOADDSDHGRFUOC-DZKIICNBSA-N 0.000 claims description 4
LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 claims description 4
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims description 4
108010055341 glutamyl-glutamic acid Proteins 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
108010090333 leucyl-lysyl-proline Proteins 0.000 claims description 4
108010038320 lysylphenylalanine Proteins 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
108010051110 tyrosyl-lysine Proteins 0.000 claims description 4
LSMDIAAALJJLRO-XQXXSGGOSA-N Ala-Thr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LSMDIAAALJJLRO-XQXXSGGOSA-N 0.000 claims description 3
230000003196 chaotropic effect Effects 0.000 claims description 3
REPBGZHJKYWFMJ-KKUMJFAQSA-N Leu-Lys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N REPBGZHJKYWFMJ-KKUMJFAQSA-N 0.000 claims description 2
238000000605 extraction Methods 0.000 claims description 2
238000001556 precipitation Methods 0.000 claims description 2
238000005063 solubilization Methods 0.000 claims description 2
230000007928 solubilization Effects 0.000 claims description 2
OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 claims 1
229940079593 drug Drugs 0.000 abstract 1
238000004007 reversed phase HPLC Methods 0.000 description 17
230000000694 effects Effects 0.000 description 16
239000000203 mixture Substances 0.000 description 15
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
210000004027 cell Anatomy 0.000 description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
229930195725 Mannitol Natural products 0.000 description 7
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 7
BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000000594 mannitol Substances 0.000 description 7
235000010355 mannitol Nutrition 0.000 description 7
239000000047 product Substances 0.000 description 7
230000010412 perfusion Effects 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
238000010533 azeotropic distillation Methods 0.000 description 5
238000001142 circular dichroism spectrum Methods 0.000 description 5
238000010828 elution Methods 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
238000002798 spectrophotometry method Methods 0.000 description 5
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000008103 glucose Substances 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
230000001590 oxidative effect Effects 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
238000012360 testing method Methods 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
235000019253 formic acid Nutrition 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011068 loading method Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
239000011148 porous material Substances 0.000 description 3
239000002994 raw material Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
-1 sulphhydryl group Chemical group 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
238000004737 colorimetric analysis Methods 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
230000002073 mitogenetic effect Effects 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
230000001173 tumoral effect Effects 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 description 1
101100315627 Caenorhabditis elegans tyr-3 gene Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 description 1
101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 1
101100205180 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-6 gene Proteins 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
101150006914 TRP1 gene Proteins 0.000 description 1
VPZKQTYZIVOJDV-LMVFSUKVSA-N Thr-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(O)=O VPZKQTYZIVOJDV-LMVFSUKVSA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000008512 biological response Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002983 circular dichroism Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
238000007865 diluting Methods 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000004880 explosion Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000001879 gelation Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
150000002357 guanidines Chemical class 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
239000000413 hydrolysate Substances 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
230000001012 protector Effects 0.000 description 1
238000010405 reoxidation reaction Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000005185 salting out Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
238000010583 slow cooling Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000003774 sulfhydryl reagent Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Analytical Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)

IL9097589A 1988-07-28 1989-07-14 Non-glycosylated, recombinant human il2 in reduced form, the process for obtaining it and its use as a medicament IL90975A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8810184A FR2635527B1 (fr)	1988-07-28	1988-07-28	Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament

Publications (2)

Publication Number	Publication Date
IL90975A0 IL90975A0 (en)	1990-02-09
IL90975A true IL90975A (en)	1994-11-28

Family

ID=9368873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9097589A IL90975A (en)	1988-07-28	1989-07-14	Non-glycosylated, recombinant human il2 in reduced form, the process for obtaining it and its use as a medicament

Country Status (21)

Country	Link
US (2)	US5874076A (de)
EP (1)	EP0353150B1 (de)
JP (1)	JP3016793B2 (de)
KR (1)	KR0131070B1 (de)
CN (1)	CN1036532C (de)
AT (1)	ATE110783T1 (de)
AU (1)	AU624625B2 (de)
DE (1)	DE68917826T2 (de)
DK (1)	DK370489A (de)
ES (1)	ES2058573T3 (de)
FI (1)	FI96209C (de)
FR (1)	FR2635527B1 (de)
HU (1)	HU207099B (de)
IE (1)	IE64232B1 (de)
IL (1)	IL90975A (de)
MX (1)	MX16912A (de)
NZ (1)	NZ230111A (de)
PT (1)	PT91295B (de)
RU (1)	RU2105011C1 (de)
UA (1)	UA26846C2 (de)
ZA (1)	ZA895419B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2660863B1 (fr) *	1990-04-17	1994-01-21	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
FR2668368B1 (fr) *	1990-10-30	1995-03-10	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
DE69031596T2 (de) *	1990-11-23	1998-02-26	Roussel Uclaf	Verfahren zur herstellung eines proteins gehörend zu der klasse der cytokine, das mindestens eine intramolekulare disulfidbrücke enthält, durch oxidation bei einem ph-wert kleiner als 5.0 des entsprechenden rekombinanten reduzierten proteins
FR2671728B1 (fr) *	1991-01-17	1995-01-20	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des pneumathorax.
FR2684878B1 (fr) *	1991-12-12	1994-02-11	Roussel Uclaf	Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US6470207B1 (en) *	1999-03-23	2002-10-22	Surgical Navigation Technologies, Inc.	Navigational guidance via computer-assisted fluoroscopic imaging
US20050203578A1 (en) *	2001-08-15	2005-09-15	Weiner Michael L.	Process and apparatus for treating biological organisms
RU2372356C2 (ru) *	2003-08-07	2009-11-10	Займоджинетикс, Инк.	Полипептид с антивирусной активностью, его получение и применение
KR102777151B1 (ko)	2017-11-21	2025-03-05	더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티	인터루킨-2의 부분 효능제
CN111944036B (zh)	2019-05-14	2024-09-06	上海盖浦生物科技有限公司	一种增殖免疫细胞的突变体蛋白
WO2021146436A2 (en)	2020-01-14	2021-07-22	Synthekine, Inc.	Biased il2 muteins methods and compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1341562C (en) *	1982-03-31	2007-11-27	Tadatsugu Taniguchi	Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
US5643566A (en) *	1982-09-23	1997-07-01	Cetus Corporation	Formulation processes for lipophilic proteins
US4518584A (en) *	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
JPS60115528A (ja) *	1983-11-28	1985-06-22	Takeda Chem Ind Ltd	ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
US4569790A (en) *	1984-03-28	1986-02-11	Cetus Corporation	Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en) *	1984-03-28	1986-08-05	Cetus Corporation	Pharmaceutical compositions of microbially produced interleukin-2
EP0158487B1 (de) *	1984-04-09	1991-08-28	Takeda Chemical Industries, Ltd.	Stabile Interleukin-2-Zusammensetzung
US4654830A (en) *	1984-11-27	1987-03-31	Monolithic Memories, Inc.	Method and structure for disabling and replacing defective memory in a PROM
US4690915A (en) *	1985-08-08	1987-09-01	The United States Of America As Represented By The Department Of Health And Human Services	Adoptive immunotherapy as a treatment modality in humans
JPH0829113B2 (ja) *	1986-11-11	1996-03-27	武田薬品工業株式会社	ヒトインタ−ロイキン−２の製造法

1988
- 1988-07-28 FR FR8810184A patent/FR2635527B1/fr not_active Expired - Fee Related
1989
- 1989-07-14 IL IL9097589A patent/IL90975A/en unknown
- 1989-07-17 ZA ZA895419A patent/ZA895419B/xx unknown
- 1989-07-25 MX MX1691289A patent/MX16912A/es unknown
- 1989-07-26 DE DE68917826T patent/DE68917826T2/de not_active Expired - Lifetime
- 1989-07-26 AT AT89402124T patent/ATE110783T1/de not_active IP Right Cessation
- 1989-07-26 EP EP89402124A patent/EP0353150B1/de not_active Expired - Lifetime
- 1989-07-26 ES ES89402124T patent/ES2058573T3/es not_active Expired - Lifetime
- 1989-07-27 JP JP1192769A patent/JP3016793B2/ja not_active Expired - Lifetime
- 1989-07-27 HU HU893827A patent/HU207099B/hu not_active IP Right Cessation
- 1989-07-27 NZ NZ230111A patent/NZ230111A/en unknown
- 1989-07-27 DK DK370489A patent/DK370489A/da not_active Application Discontinuation
- 1989-07-27 PT PT91295A patent/PT91295B/pt not_active IP Right Cessation
- 1989-07-27 FI FI893587A patent/FI96209C/fi not_active IP Right Cessation
- 1989-07-27 IE IE244389A patent/IE64232B1/en not_active IP Right Cessation
- 1989-07-27 UA UA5010517A patent/UA26846C2/uk unknown
- 1989-07-28 CN CN89106242A patent/CN1036532C/zh not_active Expired - Fee Related
- 1989-07-28 AU AU39024/89A patent/AU624625B2/en not_active Ceased
- 1989-07-28 KR KR1019890010832A patent/KR0131070B1/ko not_active Expired - Fee Related
1992
- 1992-01-08 RU SU5010517A patent/RU2105011C1/ru active
1995
- 1995-10-17 US US08/544,092 patent/US5874076A/en not_active Expired - Fee Related
1996
- 1996-02-12 US US08/601,434 patent/US5814314A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
FI96209C (fi)	1996-05-27
ES2058573T3 (es)	1994-11-01
ZA895419B (en)	1990-09-26
PT91295A (pt)	1990-02-08
JP3016793B2 (ja)	2000-03-06
JPH02209896A (ja)	1990-08-21
FI96209B (fi)	1996-02-15
HUT51647A (en)	1990-05-28
IE892443L (en)	1990-01-28
EP0353150B1 (de)	1994-08-31
IL90975A0 (en)	1990-02-09
DK370489A (da)	1990-01-29
IE64232B1 (en)	1995-07-26
AU3902489A (en)	1990-02-01
ATE110783T1 (de)	1994-09-15
UA26846C2 (uk)	1999-12-29
KR0131070B1 (ko)	1998-04-11
FI893587A0 (fi)	1989-07-27
EP0353150A1 (de)	1990-01-31
FI893587L (fi)	1990-01-29
AU624625B2 (en)	1992-06-18
CN1036532C (zh)	1997-11-26
MX16912A (es)	1993-10-01
DE68917826D1 (de)	1994-10-06
DE68917826T2 (de)	1995-01-12
US5874076A (en)	1999-02-23
DK370489D0 (da)	1989-07-27
KR900001854A (ko)	1990-02-27
US5814314A (en)	1998-09-29
HU207099B (en)	1993-03-01
CN1042377A (zh)	1990-05-23
PT91295B (pt)	1995-03-01
RU2105011C1 (ru)	1998-02-20
FR2635527B1 (fr)	1992-06-12
NZ230111A (en)	1992-04-28
FR2635527A1 (fr)	1990-02-23

Legal Events

Date	Code	Title
1999-12-31	KB	Patent renewed
2000-06-01	HCE	Change of name and address of proprietor(s)
2003-01-12	HCA	Change of name of proprietor(s) after amalgamation
2003-10-31	KB	Patent renewed
2007-08-19	KB	Patent renewed

Publication	Publication Date	Title
US4604377A (en)	1986-08-05	Pharmaceutical compositions of microbially produced interleukin-2
JP2961189B2 (ja)	1999-10-12	ヒトインターロイキン２の活性を有するポリペプチドからなることを特徴とする白血病を治療するための医薬組成物
NZ202190A (en)	1987-06-30	Human immune interferon : production by recombinant dna technology
EP0211835B1 (de)	1990-01-03	Pharmazeutische zusammensetzungen von mikrobenerzeugtem interleukin-2
US5814314A (en)	1998-09-29	Non-glycosylated, recombinant human IL 2 in reduced form
CN103923209B (zh)	2016-06-22	一种Lambda干扰素突变体及聚乙二醇衍生物
NZ203364A (en)	1986-07-11	Method for purifying human immune interferon;homogeneous human immune interferon
JP2653061B2 (ja)	1997-09-10	新規ポリペプチドおよびその製造法
KR100524872B1 (ko)	2005-11-01	인터페론 베타의 정제방법
IE61444B1 (en)	1994-11-02	Process for preparing and purifying interferon
US5157004A (en)	1992-10-20	Polypeptides and production thereof
EP0401379B1 (de)	1994-06-15	Stabilisierte interleukin-1-beta enthaltende zusammensetzung
EP2195338B1 (de)	2013-12-25	N-terminal modifiziertes interferon-alpha
JP2589094B2 (ja)	1997-03-12	抗悪性腫瘍剤
CN1448405A (zh)	2003-10-15	人截短型重组可溶性trail－170蛋白及其在制备肿瘤治疗药物中的应用
CA1283356C (en)	1991-04-23	Pharmaceutical compositions of microbially produced interleukin-2
JPH022390A (ja)	1990-01-08	新規なヒト顆粒球マクロファージコロニー刺激因子
JPH05186367A (ja)	1993-07-27	高脂血症治療薬
JPH07165792A (ja)	1995-06-27	精製された蛋白質
JPH0764871B2 (ja)	1995-07-12	蛋白質の相互分離方法